OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Médecins Sans Frontières in Amudat, eastern Uganda. RESULTS: Between 2000 and 2005, of 3483 clinically suspect patients, 53% were confirmed with primary VL. Sixty-two per cent were children <16 years of age with a male/female ratio of 2.2. The overall case-fatality rate during pentavalent antimonial (n = 1641) or conventional amphotericin B treatment (n = 217) was 3.7%. There was no difference in the case-fatality rate between treatment groups (P > 0.20). The main risk factors for in-hospital death identified by a multivariate analysis were age <6 years and >15 years, concomitant tuberculosis or hepatopathy, and drug-related adverse events. The case-fatality rate among patients >45 years of age was strikingly high (29.0%). CONCLUSION: Subgroups of VL patients at higher risk of death during treatment with drugs currently available in Uganda were identified. Less toxic drugs should be evaluated and used in these patients.
OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Médecins Sans Frontières in Amudat, eastern Uganda. RESULTS: Between 2000 and 2005, of 3483 clinically suspect patients, 53% were confirmed with primary VL. Sixty-two per cent were children <16 years of age with a male/female ratio of 2.2. The overall case-fatality rate during pentavalent antimonial (n = 1641) or conventional amphotericin B treatment (n = 217) was 3.7%. There was no difference in the case-fatality rate between treatment groups (P > 0.20). The main risk factors for in-hospital death identified by a multivariate analysis were age <6 years and >15 years, concomitant tuberculosis or hepatopathy, and drug-related adverse events. The case-fatality rate among patients >45 years of age was strikingly high (29.0%). CONCLUSION: Subgroups of VL patients at higher risk of death during treatment with drugs currently available in Uganda were identified. Less toxic drugs should be evaluated and used in these patients.
Authors: Jorge A Pastor-Santiago; Susana Chávez-López; Carmen Guzmán-Bracho; Ana Flisser; Angélica Olivo-Díaz Journal: Am J Trop Med Hyg Date: 2012-01 Impact factor: 2.345
Authors: Michael O Harhay; Piero L Olliaro; Michel Vaillant; François Chappuis; María Angeles Lima; Koert Ritmeijer; Carlos Henrique Costa; Dorcas Lamounier Costa; Suman Rijal; Shyam Sundar; Manica Balasegaram Journal: Am J Trop Med Hyg Date: 2011-04 Impact factor: 2.345
Authors: Valdelaine Etelvina Miranda de Araújo; Maria Helena Franco Morais; Ilka Afonso Reis; Ana Rabello; Mariângela Carneiro Journal: PLoS Negl Trop Dis Date: 2012-02-07
Authors: Erika van den Bogaart; Marieke M Z Berkhout; Emily R Adams; Pètra F Mens; Elizabeth Sentongo; Dawson B Mbulamberi; Masja Straetemans; Henk D F H Schallig; Francois Chappuis Journal: PLoS Negl Trop Dis Date: 2012-04-10
Authors: Angelita F Druzian; Albert S de Souza; Diogo N de Campos; Julio Croda; Minoru G Higa; Maria Elizabeth C Dorval; Mauricio A Pompilio; Polliana A de Oliveira; Anamaria M M Paniago Journal: PLoS Negl Trop Dis Date: 2015-08-14
Authors: Erika van den Bogaart; Marieke M Z Berkhout; Ayman B Y M Nour; Pètra F Mens; Al-Badawi A Talha; Emily R Adams; Hashim B M Ahmed; Samira H Abdelrahman; Koert Ritmeijer; Bakri Y M Nour; Henk D F H Schallig Journal: BMC Public Health Date: 2013-04-11 Impact factor: 3.295